Early Assessment of Response to Treatment of Metastatic LUng Tumors Based on CIrculating Tumor DNA (ELUCID)
Non-controlled Prospective Pilot Study Assessing Prognostic Performance of Circulating Tumour DNA Kinetic Analysis for Monitoring Response to Treatment of Metastatic Non-small Cell Lung Cancers
Sponsor: Centre Hospitalier Departemental Vendee
A NA clinical study on Metastatic Non-small Cell Lung Cancer, this trial is completed. The trial is conducted by Centre Hospitalier Departemental Vendee and has accumulated 11 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Jan 2026 — Present [monthly]
Completed NA
-
Sep 2024 — Jan 2026 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2022 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Apr 2022 — Jul 2022 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 6 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Recruiting NA
-
Jul 2020 — Jan 2021 [monthly]
Recruiting NA
-
Nov 2019 — Jul 2020 [monthly]
Recruiting NA
-
Aug 2019 — Nov 2019 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jul 2019 — Aug 2019 [monthly]
Not Yet Recruiting NA
-
May 2019 — Jul 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Centre Hospitalier Departemental Vendee
For direct contact, visit the study record on ClinicalTrials.gov .